Neutralizing antibody assay and uses therefor
AssigneeGenentech, Inc.
InventorsMaureen Beresini, An Song
Life of this patent
Estimating the term…
Abstract
A method of detecting neutralizing antibodies to a therapeutic antibody such as a CD20 antibody is described. The assay can be used to determine the efficacy of the antibody in a method of immunotherapy.
Claims21
A method for evaluating the efficacy of an antibody that binds CD20 comprising measuring the ability of a biological sample from a patient treated with the CD20 antibody to block a biological activity of the CD20 antibody.
A method of immunotherapy comprising
- administering an antibody that binds CD20 to a patient;
- and
- measuring the ability of a biological sample from the patient to block a biological activity of the CD20 antibody.
A method of detecting neutralizing antibodies to a therapeutic antibody comprising
- exposing cells that express an antigen to which the therapeutic antibody binds to complement in the presence of the therapeutic antibody and a biological sample from a patient treated therewith;
- and
- determining complement-dependent cytotoxicity (CDC) activity of the therapeutic antibody, wherein a reduction in the CDC activity indicates the presence of neutralizing antibodies in the biological sample.
A method of evaluating the efficacy of an antagonist that binds a B cell surface marker comprising measuring the ability of a biological sample from a patient treated with the antagonist to block a biological activity of the antagonist.
A method of immunotherapy comprising
- administering an antibody that binds a B cell surface marker to a patient;
- and
- measuring the ability of a biological sample from the patient to block a biological activity of the antibody.
Dependencies are inferred from the claim text.